Synapticure Inc.

Marissa Plescia at MedCity News interviewed Synapticure CEO, co-founder, and caregiver Sandra Abrevaya on our plans to revolutionize neurodegenerative care & treatment nationwide. Read how Synapticure is leading the new era of  care: https://lnkd.in/gtF7kb69 #HealthcareInnovation #SeriesA #VirtualCare #Neurology #Neurocare

Moments like these remind us of the impact personalized, compassionate care can have on patients and families navigating neurodegenerative diseases. Our team is here to provide not just medical expertise but also meaningful support to renew hope for the future. Discover more about our mission and care approach at https://lnkd.in/gNvZEu7Y #neurocare #virtualcare #Alzheimers #Parkinsons #ALS #Huntingtons

Synapticure Raises $25M Series A https://lnkd.in/gipXPPBj Your go-to for local business news. Follow citybiz Get Started For Free - https://lnkd.in/eCbDHkxj Synapticure Inc. B Capital CommonSpirit Health CVS Health Ventures RA Capital Management Nexus NeuroTech Ventures GV (Google Ventures) Optum Ventures Rock Health Capital Sandra Abrevaya Brian Wallach Peter Wallach Jason Langheier MD, MPH Jonathan Hirsch #Synapticure #Raises #FundRaise #SeriesA #virtual #care #company #Citybiz #Citybizco #Citybizlist #CitybizNews

Synapticure’s care journey goes beyond a diagnosis. Our experts—from neurologists to patient advocates—are here to provide continuous, compassionate support tailored to our patients’ lives. With our virtual model, patients can access leading neurodegenerative care and treatment from wherever they are, with a team that truly understands their needs. Our team helps people and their families feel empowered to focus on what matters most, knowing they have Synapticure’s full support. Learn more: https://lnkd.in/gNvZEu7Y #neurocare #virtualcare #Alzheimers #Parkinsons #ALS #Huntingtons

I am so proud of Sandra Abrevaya and the Synapticure Inc. team for raising the A. I am also grateful to B Capital and the other investors for believing in us. LFG! https://lnkd.in/giCEz5hh

Like so many people, my relationship to dementia is personal. As the caregiver to a close family member, I’ve experienced firsthand: - The struggle to obtain a diagnosis, and the carousel of doctors and services that never seem to make a difference - The overwhelming burden of taking on accountability for another adult’s finances, belongings, healthcare decisions and day to day decisions while trying to manage my own - The heartbreak in watching someone you love struggle with sadness, anger, and confusion, especially the days they forget who you are, or that you have a young daughter It is from this place I came to Synapticure Inc., and found purpose and community in helping to create the support system I wish I had from the start – specialists I don’t have to wait 6 months and drive hours to see for 15 mins, a care navigator I know by name who I call any time for help, and care that isn’t just about modifying the dosage of meds -- but instead, figuring out how to help me be a caregiver, a husband, a father, and professional without going off the rails. I am so proud of what our team is building, not just for Alzheimer’s and related Dementias, but also Parkinson’s, ALS and other neurodegenerative disorders. In the last year we:  - Launched partnerships with leading health systems, ACOs and payers across the country to bring our model of care to more families  - Doubled our practice to care for more than 4,000 patients in all 50 states, including more than 1,000 patients through the new CMS Dementia GUIDE model (and we’re just getting started) - Continued to provide visits in 2-3 weeks, with access to our care navigators 24/7 in any time zone   - Gathered outcomes data to publish early next year highlighting the impact we’ve had on quality, reduced ED visits and hospitalizations, and improvements to quality of life The lived experience of our co-founders Brian Wallach, Sandra Abrevaya and Peter Wallach, and the expertise of our clinical and technology leaders like Eric Anderson MD PhD MBA FAAN, Christie (Byrne) Lightcap and so many others who pour their heart and soul into the work are what make Synapticure such a fun and rewarding place to work. And I’m grateful to partner with organizations like B Capital , GV (Google Ventures), Optum Ventures, CommonSpirit Health, CVS Health Ventures, Nexus NeuroTech Ventures, RA Capital Management, Rock Health, Martin Ventures and so many others who share a commitment to transforming care for neurodegenerative diseases. This Series A investment is an exciting milestone for Synapticure, and will enable us to continue to scale our team, pursue new partnerships and technologies, and accelerate new treatments in pursuit of our ultimate goal – cures. Read more here --> https://lnkd.in/g6cTatt7 We are growing our team, so please reach out. And, if you or a loved one is navigating a neurodegenerative condition please message me, or call us at (855) 255-5917 or email us support@synapticure.com

After our Series A funding announcement, the big question is: What’s next? In our latest blog, CEO and co-founder Sandra Abrevaya shares how Synapticure plans to make a difference in the lives of millions. Read here ➡️ https://lnkd.in/gpKFffYM #HealthcareInnovation #SandraAbrevaya #Alzheimers #Dementia #Parkinsons #Huntingtons #ALS

We’re grateful to B Capital and Adam Seabrook for leading our $25M Series A round. Your support empowers Synapticure to transform care for neurodegenerative diseases like ALS, Parkinson’s, and Alzheimer’s. Together, we’re expanding access to expert care and making a real difference for patients and caregivers across the U.S. #SeriesA #NeurodegenerativeCare #Alzheimers #Dementia #ALS #Parkinsons #SeriesA #HealthTech

Synapticure Inc., a startup building digital health tools for people with neurodegenerative conditions and their caregivers, has raised $40 million in a new round of funding to bring its approach to more people living with conditions like ALS, Parkinson’s disease and Alzheimer’s disease. B Capital led the $25 million Series A round, and health system CommonSpirit, as well as CVS Health Ventures, RA Capital Management and Nexus NeuroTech Ventures joined as new investors. Existing investors GV, Optum Ventures and Rock Health Capital also contributed. Lydia Ramsey Pflanzer writes for our #HealthTech newsletter: https://lnkd.in/eFrGBhup

We are thrilled to announce the successful completion of our Series A funding led by B Capital raising $25M to transform care and treatment for people and their families living with Alzheimer's, Parkinson’s, ALS, and beyond. This milestone marks the beginning of our next phase of growth as we work to serve the 10M people currently affected by neurodegenerative diseases. With this fund, we’ll make an even greater impact as we expand partnerships with healthcare payers and providers, fast-track clinical research, introduce new offerings, and invest in our innovative technology to ease the burden on families managing the complex needs of neurodegenerative conditions. Thank you to our new and longterm investors B Capital , CVS Health Ventures, CommonSpirit Health, GV (Google Ventures), Optum Ventures, Rock Health, RA Capital Management, Nexus NeuroTech Ventures, and to everyone who has supported us in our mission to improve neurodegenerative care and treatment thus far. We can’t wait to share what's next. Read the full announcement: ➡️ https://lnkd.in/gWZH37yn #AccessibleCare #HealthEquity #SeriesA #NeurodegenerativeCare #Alzheimers #Dementia #ALS #Parkinsons #SeriesA #HealthTech #Alzheimers #VirtualCare #VentureCapital #Startup